University of Wolverhampton, UK
Disulfican Ltd is a University of Wolverhampton’s spin out company. Disulfican uses the core research facility located at the new state of the art Rosalind Franklin Science Building in city campus of the University. Prof. Wang, the lead scientific adviser of Disulfican, also runs the experimental cancer therapeutics research group in the University with expert research fellows and students working on translation of disulfiram and other potential pipeline of drugs, for a wide range of cancers.
Jiangsu-UK Industrial Challenge Programme 2018-2020
£535k project to develop the formulation and testing of PLGA-DS as an anti-cancer therapy for FDA and EMA new drug application. In this project, our Chinese partner in Jiangsu province developed nano-encapsulated DS at GMP quality and provided it to Disulfican Ltd. We used laboratory facilities in the UK (the University of Wolverhampton and elsewhere) to examine the in vitro and in vivo anticancer activity of the newly developed nano-DS in animal cancer models. We verified the anticancer efficacy of the GMP qualified nano-DS and obtained preclinical data needed prior to undertaking formal pre-clinical development.
Biomedical Catalyst Feasibility & Primer Awards 2022-2024
£748k project to carry out Translational Development of a novel therapy for Malignant Mesothelioma. Together with a collaborating team in our development, Disulfican successfully completed work on the initial stages of developing this new therapy for Mesothelioma treatment. Promising research results have been achieved for the encapsulated drug when tested in mice with mesothelioma, including with patient-derived cells, and through this project we are carrying out the necessary evaluation of efficacy and mechanism of action so that the team can progress towards clinical trials.